SCHEMBL17107261

SCHEMBL17107261

Cn1c(-c2ccccc2)csc1=NC(=O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.69
RAB9A P51151 6/20 0.69
ALDH1A1 P00352 5/20 0.69
NPC1 O15118 5/20 0.69
TP53 P04637 1/20 0.69
HSD17B10 Q99714 1/20 0.53
ALOX5 P09917 6/20 0.49
PTGS2 P35354 6/20 0.49
POLB P06746 2/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 3/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17107260 1.00 SMN1; SMN2 (0.69) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17132000 1.00 SMN1; SMN2 (0.69) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17107184 0.91 RAB9A (0.61) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17107134 0.91 RAB9A (0.58) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17107183 0.91 RAB9A (0.61) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17107268 0.91 RAB9A (0.58) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17131986 0.91 RAB9A (0.58) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17131994 0.91 RAB9A (0.58) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17107133 0.91 RAB9A (0.58) SMN1; SMN2RAB9AALDH1A1NPC1TP53
SCHEMBL17132025 0.91 RAB9A (0.61) SMN1; SMN2RAB9AALDH1A1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE XAVIER UNIVERSITY OF LOUISIANA 2015-10-01 US claimed
US-9650369-B2 Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease XAVIER UNIVERSITY OF LOUISIANA (US) 2017-05-16 US disclosed
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE XAVIER UNIVERSITY OF LOUISIANA 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE MKI67, MIF, NUDC SMN1; SMN2 2720/4885RAB9A 1305/4885ALDH1A1 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.